Affiliation:
1. Yevdokimov Moscow State University of Medicine and Dentistry
2. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology;
Yevdokimov Moscow State University of Medicine and Dentistry
Abstract
Taking into account the modern life expectancy, a third of their lives, on average, women live in conditions of estrogen deficiency, which negatively affects the quality of life and the level of morbidity in older people. For doctors of other specialties, besides ObGyn, the climacteric period is strongly associated exclusively with hot flashes. However, early menopausal symptoms include sleep disturbances, mood changes, the risk of depression and decrease in self-esteem, sexual dysfunction. The predominance of vegetative symptoms makes the patient seek help not only from the gynecologist, but also from other specialists, however, the lack of knowledge in menopause medicine leaves them unsatisfied. In this regard, a therapeutic approach requires a comprehensive understanding of the problem.The “gold standard” for managing patients with climacteric complaints is menopausal hormone therapy. However, there are women with contraindications to this group of drugs or the predominance of vegetative symptoms, when only hormonal correction is not enough. Among alternative non-hormonal agents, inhibitors of serotonin reuptake, in particular the most popular drug venlafaxine, hold a strong leadership with proven efficacy against a complex of symptoms. Also, other medications have been studied that can stop both vasomotor and vegetative symptoms of menopause. The review presents the literature data on the role of alternative agents in the correction of vasomotor symptoms of menopause, along with the known efficacy against autonomic complaints for increasing the effectiveness of counseling for older women.
Reference49 articles.
1. Sukhikh G.T., Smetnik V.P., Yureneva S.V., Ermakova E.I., Chernukha G.E., Yakushevskaya O.V. Menopause and climacteric condition in women. Clinical guidelines. 2016. 49 p. (In Russ.) Available at: https://www.ulsu.ru/media/uploads/nina-baratyuk%40mail.ru/2017/11/02/%D0%9C%D0%B5%D0%BD%D0%BE%D0%BF%D0%B0%D1%83%D0%B7%D0%B0%20%D0%B8%20%D0%9A%D0%A1%20%D1%83%20%D0%B6%D0%B5%D0%BD%D1%89%D0%B8%D0%BD_dhJQ8WW.pdf.
2. Tella S.H., Gallagher G.H. Efficacy of desvenlafaxine succinate for menopausal hot flashes. Expert Opin Pharmacother. 2014;15(16):2407–2418. doi: 10.1517/14656566.2014.964641.
3. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–1174. doi: 10.1097/GME.0000000000000546.
4. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. doi: 10.1001/jamainternmed.2014.8063.
5. Gold E.B., Colvin A., Avis N., Bromberger J., Greendale G.A., Powell L. et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition. Am J Public Health. 2006;96(7):1226–1235. doi: 10.1001/jamainternmed.2014.8063.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献